Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Increased to Strong-Buy at Canaccord Genuity Group

Canaccord Genuity Group upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN - Free Report) from a hold rating to a strong-buy rating in a research report released on Tuesday,Zacks.com reports.

Several other equities research analysts also recently commented on the company. UBS Group downgraded Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and cut their price objective for the company from $1,130.00 to $738.00 in a report on Thursday, January 16th. Cantor Fitzgerald started coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 price objective for the company. Wells Fargo & Company dropped their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating on the stock in a report on Friday, January 10th. Bernstein Bank reduced their price target on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. Finally, Leerink Partnrs upgraded Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, February 5th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, nineteen have issued a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $945.32.

Regeneron Pharmaceuticals Stock Up 0.8 %

Regeneron Pharmaceuticals stock traded up $4.86 during mid-day trading on Tuesday, reaching $607.50. The company's stock had a trading volume of 292,299 shares, compared to its average volume of 974,587. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. Regeneron Pharmaceuticals has a 12 month low of $525.99 and a 12 month high of $1,211.20. The business's 50 day simple moving average is $637.38 and its 200 day simple moving average is $721.91. The company has a market capitalization of $66.41 billion, a price-to-earnings ratio of 15.87, a price-to-earnings-growth ratio of 2.34 and a beta of 0.44.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.79 billion during the quarter, compared to analysts' expectations of $3.76 billion. During the same quarter last year, the company earned $11.86 EPS. Regeneron Pharmaceuticals's revenue for the quarter was up 10.3% compared to the same quarter last year. As a group, research analysts anticipate that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.58%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio is currently 2.30%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. FSM Wealth Advisors LLC increased its position in Regeneron Pharmaceuticals by 17.9% during the 1st quarter. FSM Wealth Advisors LLC now owns 356 shares of the biopharmaceutical company's stock worth $226,000 after purchasing an additional 54 shares in the last quarter. Klingenstein Fields & Co. LP increased its holdings in shares of Regeneron Pharmaceuticals by 2.0% during the first quarter. Klingenstein Fields & Co. LP now owns 6,944 shares of the biopharmaceutical company's stock worth $4,404,000 after buying an additional 138 shares in the last quarter. Keybank National Association OH lifted its stake in shares of Regeneron Pharmaceuticals by 23.7% in the 1st quarter. Keybank National Association OH now owns 1,533 shares of the biopharmaceutical company's stock valued at $972,000 after acquiring an additional 294 shares during the last quarter. Rossby Financial LCC acquired a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter valued at $87,000. Finally, DAVENPORT & Co LLC bought a new stake in Regeneron Pharmaceuticals during the 1st quarter worth $271,000. Institutional investors own 83.31% of the company's stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.